Rates of Dissatisfaction High for Hidradenitis Suppurativa Care

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 7, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, April 7, 2025 -- The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high, likely due to undertreatment with available therapies, according to study published in the April issue of the Journal of Drugs in Dermatology.

Andeulazia Murdock, from the George Washington School of Medicine and Health Sciences in Washington, D.C., and colleagues distributed a survey to examine perceptions of current and emerging HS treatments and their impact on quality of life among respondents aged 18 years and older. Overall, 423 participants completed the entire survey.

The researchers found that <20 percent of respondents (76/423) were satisfied or very satisfied with current treatment options. Only 39 and/or 26 percent of the 244 patients with self-reported disease severity of Hurley stage II or III were being treated with biologics and/or hormone therapy, respectively, indicating undertreatment per current guidelines. Seventy-four percent of the respondents were unaware of U.S. Food and Drug Administration-approved treatments; more than half (56 percent) reported that these options had not been discussed by their dermatologist or health care provider. Sixty percent of respondents felt it was important to have FDA-approved therapies, believing it would result in improved physical health, mental health, and/or personal relationships (86, 78, and 60 percent, respectively).

"Our goal with this study was to highlight the multifaceted positive impact of new FDA treatments on those living with hidradenitis and the importance of pharma investment in this space," coauthor Adam Friedman, M.D., also from the George Washington School of Medicine and Health Sciences, said in a statement. "We also found that there are still significant gaps in care and dissatisfaction with current treatment approaches."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-08 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords